Exyte, Univercells fast track construction for COVID-19 vaccines
May 14, 2020 -- High-tech construction firm Exyte and biomanufacturing company Univercells Technologies are partnering for construction of modular standardized and flexible manufacturing facilities for vaccines.
Boehringer Ingelheim acquires Northern Biologics
May 14, 2020 -- Boehringer Ingelheim on May 14 announced the acquisition of Northern Biologics, including its preclinical cancer antibody pipeline.
Yumab identifies COVID-19 antibody therapy
May 13, 2020 -- German biotechnology company Yumab said it has identified a promising candidate for COVID-19 antibody therapy.
BARDA gives $20M to Sabin Vaccine Institute for vaccines
May 13, 2020 -- The U.S. Biomedical Advanced Research and Development Authority (BARDA) awarded the Sabin Vaccine Institute $20 million to manufacture and release clinical Ebola and Marburg vaccine materials developed by its partner, ReiThera. The funding will also support nonclinical studies to evaluate their efficacy and immune response.
Neovii, Tel Aviv University partner for COVID-19 vaccine
May 13, 2020 -- Israeli firm Ramot has inked a license agreement with Neovii, a Swiss-based biopharmaceutical company, for the research and development of a COVID-19 vaccine.
Specifica transfers antibody discovery platform to Bayer
May 12, 2020 -- Specifica announced the transfer of its Generation 3 antibody libraries to Bayer under an agreement that will enable the company to develop antibody-based therapeutics.
Bio-Techne releases new T-cell activation kit
May 11, 2020 -- Bio-Techne has released a new kit for cell and gene therapy manufacturing called GMP Cloudz Human T Cell Activation.
Thermo Fisher to double viral vector manufacturing capacity
May 11, 2020 -- Thermo Fisher Scientific is expanding its viral vector development and manufacturing services with construction of a new commercial manufacturing site in Plainville, MA. The $180 million facility will more than double the company's current commercial viral vector capacity and support its growing gene therapy and vaccine business.
ABL Europe to manufacture Themis SARS-CoV-2 vaccine in France
May 11, 2020 -- Biopharmaceutical company Themis and contract development and manufacturing organization ABL Europe announced that they have signed an agreement to manufacture a SARS-CoV-2 vaccine candidate in preparation for clinical trials.
Sorrento, Mount Sinai to develop targeted SARS-CoV-2 antibody treatment
May 8, 2020 -- Sorrento Therapeutics and Mount Sinai Health System have joined forces to develop an antibody therapy called COVI-Shield to treat COVID-19.
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter